Rifaximin is an oral antibiotic that is used primarily to treat certain bacterial infections of the gut. Its therapeutic purpose is to reduce the load of specific bacteria that cause travelers diarrhea and postoperative complications. The drug works by targeting the bacterial ribosome and inhibiting protein synthesis in susceptible organisms. Because it is poorly absorbed in the intestines it stays largely confined to the gut lumen where it can act directly on resident microbes. This localized action helps to modulate the microbial balance and decrease inflammation associated with conditions such as irritable bowel syndrome with diarrhea. The active substance thus reduces the proliferation of harmful bacteria while sparing the normal flora and thereby supports the body's natural recovery processes. Overall Rifaximin provides a targeted antimicrobial effect that complements other measures aimed at restoring intestinal health.

Rifaximin is a broad-spectrum antibiotic derived from rifamycin that is administered orally in tablet form. It is primarily used to treat travel-associated diarrhea caused by invasive strains of escherichia coli and to manage recurrent episodes of hepatic encephalopathy in patients with liver disease. Its therapeutic effect stems from the inhibition of bacterial rna polymerase which disrupts protein synthesis in susceptible microbes. By limiting bacterial proliferation in the gastrointestinal lumen it reduces toxin production and inflammation associated with pathogenic infection. Because it is minimally absorbed into systemic circulation most of the compound remains in the gut where it acts locally without significant systemic exposure. This localized activity and low systemic exposure contribute to its safety profile compared with older antibiotics used for similar indications.

Rifaximin is generally well tolerated but can cause gastrointestinal disturbances such as abdominal discomfort. Some patients report diarrhea which may range from mild to more pronounced. Nausea and occasional vomiting have been observed in clinical studies. Headache and dizziness are among the less frequent side effects reported. Flatulence and bloating may occur due to changes in intestinal flora. Rarely elevated liver enzymes have been detected in laboratory tests. Most of these effects are mild and resolve without medical intervention.

Rifaximin may cause headache in some patients. Nausea or abdominal discomfort can also occur. Gas or flatulence is another reported effect. Some individuals experience dizziness or drowsiness. Fatigue may be observed during treatment. Skin reactions such as rash are possible but less common. Changes in taste perception have been noted in clinical reports.